Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: June 2012

Open Access Gateway

Disseminated Intracranial Ewing’s Sarcoma in an Adult:A Rare and Difficult Diagnosis

Lou E.a · Sumrall A.L.a · Cummings T.J.a · Korones D.N.b · Weaver S.A.c · Peters K.B.a

Author affiliations

aThe Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, N.C., bUniversity of Rochester Medical Center, Rochester, N.Y., and cAlbany Medical Center, New York, N.Y., USA

Corresponding Author

Emil Lou, MD, PhD

Division of Hematology, Oncology and Transplantation

MMC Code 480, 420 Delaware Street SE

Minneapolis, MN 55455 (USA)

Tel. +1 612 625 1110, E-Mail emil-lou@umn.edu

Related Articles for ""

Case Rep Oncol 2012;5:325–331

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The Ewing sarcoma family of tumors comprises a rare class of cancers of mesenchymal origin. Cases of Ewing’s sarcoma in the central nervous system – specifically, intracranial Ewing’s – are extremely rare. Almost all reported cases have occurred in children. However, this rare presentation can also occur in the adult population. It is important to distinguish these tumors from primitive neuroectodermal tumors at the time of diagnosis. Testing for EWSR1(22q12) gene rearrangement using fluorescence in situ hybridization is a useful tool for making the distinction between these 2 similar but distinct entities. We present here the case of a middle-aged male patient with intracranial Ewing’s sarcoma, and discuss diagnostic challenges and potential new treatment approaches for this rare disease.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: June 2012

Published online: June 21, 2012
Issue release date: May – August

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

eISSN: 1662-6575 (Online)

For additional information: http://www.karger.com/CRO

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.